FRE Stock Analysis: Fresenius SE & Co. KGaA | XETRA
Medical Care Facilities | XETRA, Germany | Market Cap: 22.569m EUR | 12M Return: -4.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 52.2M
EPS Trend: 97.9%
Qual. Beats: 1
Rev. Trend: -79.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.
Fresenius SE & Co. KGaA is a German healthcare group founded in 1912 and headquartered in Bad Homburg vor der Höhe, listed on XETRA under the ticker FRE. It operates through two main segments: Fresenius Kabi, which supplies biopharmaceuticals, clinical nutrition, IV generics, IV fluids, biosimilars, and MedTech products (such as infusion pumps and apheresis machines) for critically and chronically ill patients, and Fresenius Helios, which runs hospitals, outpatient clinics, occupational health centers, and diagnostic services across multiple regions.
The company has a strategic collaboration with SAP SE and Avelios Medical GmbH to develop a cloud-native, modular hospital information system with AI integration. Freseniuss legal form is a Kommanditgesellschaft auf Aktien (KGaA), a German partnership limited by shares, reflecting its hybrid structure between a general partnership and a stock corporation.
- German hospital reform pressures Helios reimbursement and margins
- Kabi biosimilars and IV generics face US pricing competition
- Deleveraging continues post-Vamed divestiture improving balance sheet
| Net Income: 1.47b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.44 > 1.0 |
| NWC/Revenue: 10.98% < 20% (prev 16.18%; Δ -5.20% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.92b > Net Income 1.47b |
| Net Debt (11.2b) to EBITDA (3.60b): 3.12 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (561.0m) vs 12m ago -0.40% < -2% |
| Gross Margin: 25.25% > 18% (prev 24.48%; Δ 0.77% > 0.5%) |
| Asset Turnover: 53.85% > 50% (prev 51.17%; Δ 2.68% > 0%) |
| Interest Coverage Ratio: 7.79 > 6 (EBIT TTM 2.47b / Interest Expense TTM 317.0m) |
| A: 0.06 (Total Current Assets 12.1b - Total Current Liabilities 9.54b) / Total Assets 42.4b |
| B: 0.35 (Retained Earnings 14.8b / Total Assets 42.4b) |
| C: 0.06 (EBIT TTM 2.47b / Avg Total Assets 42.8b) |
| D: 0.90 (Book Value of Equity 19.8b / Total Liabilities 21.9b) |
| Altman-Z'' = 2.86 = A |
| DSRI: 1.06 (Receivables 5.68b/5.16b, Revenue 23.0b/22.1b) |
| GMI: 0.97 (GM 24.48% / 25.25%) |
| AQI: 0.97 (AQ_t 0.49 / AQ_t-1 0.50) |
| SGI: 1.04 (Revenue 23.0b / 22.1b) |
| TATA: -0.03 (NI 1.47b - CFO 2.92b) / TA 42.4b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of June 30, 2026, the stock is trading at EUR 39.82 with a total of 746,553 shares traded. Over the past week, the price has changed by +0.53%, over one month by +8.47%, over three months by -8.21% and over the past year by -4.10%.
Current recommended Stop Loss: 38.60 (which is 3.1% or 1.4 ATR below the current price).
Fresenius SE & Co. KGaA has no consensus analysts rating.
P/E Trailing = 14.9515
P/E Forward = 11.3895
P/S = 0.9819
P/B = 1.136
P/EG = 0.7344
Revenue TTM = 23.0b EUR
EBIT TTM = 2.47b EUR
EBITDA TTM = 3.60b EUR
Long Term Debt = 8.31b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.37b EUR (from shortTermDebt, last quarter)
Debt = 13.3b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.40b
Net Debt = 11.2b EUR (calculated: Debt 13.3b - CCE 2.06b)
Enterprise Value = 33.8b EUR (22.6b + Debt 13.3b - CCE 2.06b)
Interest Coverage Ratio = 7.79 (Ebit TTM 2.47b / Interest Expense TTM 317.0m)
EV/FCF = 23.34x (Enterprise Value 33.8b / FCF TTM 1.45b)
FCF Yield = 4.28% (FCF TTM 1.45b / Enterprise Value 33.8b)
FCF Margin = 6.29% (FCF TTM 1.45b / Revenue TTM 23.0b)
Net Margin = 6.38% (Net Income TTM 1.47b / Revenue TTM 23.0b)
Gross Margin = 25.25% ((Revenue TTM 23.0b - Cost of Revenue TTM 17.2b) / Revenue TTM)
Gross Margin QoQ = 26.38% (prev 24.76%)
Tobins Q-Ratio = 0.80 (Enterprise Value 33.8b / Total Assets 42.4b)
Interest Expense / Debt = 2.38% (Interest Expense 317.0m / Debt 13.3b)
Taxrate = 26.65% (574.0m / 2.15b)
NOPAT = 1.81b (EBIT 2.47b * (1 - 26.65%))
Current Ratio = 1.27 (Total Current Assets 12.1b / Total Current Liabilities 9.54b)
Debt / Equity = 0.67 (Debt 13.3b / totalStockholderEquity, last quarter 19.8b)
Debt / EBITDA = 3.12 (Net Debt 11.2b / EBITDA 3.60b)
Debt / FCF = 7.76 (Net Debt 11.2b / FCF TTM 1.45b)
Total Stockholder Equity = 18.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.44% (Net Income 1.47b / Total Assets 42.4b)
RoE = 7.76% (Net Income TTM 1.47b / Total Stockholder Equity 18.9b)
RoCE = 9.06% (EBIT 2.47b / Capital Employed (Equity 18.9b + L.T.Debt 8.31b))
RoIC = 5.32% (NOPAT 1.81b / Invested Capital 34.0b)
WACC = 4.83% (E(22.6b)/V(35.9b) * Re(6.64%) + D(13.3b)/V(35.9b) * Rd(2.38%) * (1-Tc(0.27)))
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -30.43 | Cagr: -0.18%
[DCF] Terminal Value 73.42% ; FCFF base≈1.54b ; Y1≈1.37b ; Y5≈1.15b
[DCF] Fair Price = 12.61 (EV 18.3b - Net Debt 11.2b = Equity 7.10b / Shares 563.2m; r=8.35% [WACC [floored]]; 5y FCF grow -13.18% → 2.50% )
EPS Correlation: 97.93 | EPS CAGR: 18.16% | SUE: 1.07 | # QB: 1
Revenue Correlation: -79.83 | Revenue CAGR: -18.14% | SUE: 0.16 | # QB: 0
EPS next Quarter (2026-09-30): EPS=0.78 | Chg30d=-2.57% | Revisions=-14% | Analysts=3
EPS current Year (2026-12-31): EPS=3.58 | Chg30d=-0.04% | Revisions=-20% | GrowthEPS=+1.3% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=3.90 | Chg30d=-0.02% | Revisions=-47% | GrowthEPS=+8.8% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: -47%